Evinacumab

Introduction Overview

Generic Name

evinacumab

Brand Name

Evkeeza

Dosage Form

intravenous infusion

Drug Class

Miscellaneous antihyperlipidemic agents

Pharmacokinetics

Absorption:
Evkeeza (evinacumab) is administered intravenously, thereby bypassing the gastrointestinal tract and resulting in 100% bioavailability. Its absorption phase is essentially immediate following intravenous (IV) infusion, which is typically administered over 60 minutes. Due to the intravenous route, there is no variability due to first-pass metabolism or gastrointestinal factors, leading to predictable systemic exposure.

Distribution:
Following IV administration, evinacumab, as a monoclonal antibody, distributes primarily into the vascular and interstitial spaces. Monoclonal antibodies generally have a distribution volume approximating plasma volume, often ranging between 3-5 L. Evinacumab is expected to have a limited distribution beyond extracellular fluids due to its large molecular size (~150 kDa), restricting its penetration into tissues and intracellular compartments. It binds specifically to the angiopoietin-like 3 (ANGPTL3) protein with high affinity, which influences its pharmacodynamic effects.

Metabolism:
Evinacumab is metabolized via proteolytic catabolism similar to endogenous IgG antibodies. It undergoes degradation into small peptides and amino acids through the reticuloendothelial system and cellular processes. It is not metabolized by hepatic cytochrome P450 enzymes, reducing the risk of metabolic drug interactions. The elimination pathways reflect those typical of IgG monoclonal antibodies, including target-mediated drug disposition with nonlinear kinetics at some dose ranges, although clinically evinacumab displays predictable kinetics at therapeutic doses.

Elimination:
The elimination half-life of evinacumab is reported to be approximately 3 to 4 weeks, supporting once-monthly dosing. Clearance occurs via proteolytic degradation and target-mediated elimination upon binding to ANGPTL3. Renal excretion is negligible given the large molecular size. The long half-life enables sustained suppression of ANGPTL3 activity, maintaining reduced LDL cholesterol levels. Clinical evidence supports a dosing interval of every 4 weeks via IV infusion for optimal therapeutic effect.

Dosage Forms

Available Dosage Forms:
- Single-Dose Vial 1,200 mg/8 mL (150 mg/mL)
- Single-Dose Vial 345 mg/2.3 mL (150 mg/mL)

Dosages for Adults and Adolescents:
- Adults (≥18 years) with Homozygous Familial Hypercholesterolemia (HoFH): 15 mg/kg administered via intravenous infusion once monthly (every 4 weeks).
- Pediatric patients aged 12 years and older with HoFH: 15 mg/kg via intravenous infusion once monthly.

Specific Patient Populations:
- The safety and efficacy of evinacumab in patients younger than 5 years have not been established.
- For pediatric patients age 5 to less than 12 years, dosing regimens are not currently fully defined due to limited clinical data.
- Dosage adjustments are not typically required based on renal or hepatic impairment, consistent with monoclonal antibody elimination pathways.

Clinical Considerations:
- Evkeeza infusion must be administered by a healthcare professional via IV infusion over approximately 60 minutes.
- If an infusion appointment is missed, rescheduling should be sought promptly to maintain therapeutic LDL-C control.
- Assessment of LDL-C levels can be done as soon as 2 weeks after initiating therapy to monitor response.
- Evkeeza is used adjunctively with other LDL-C lowering therapies; concomitant medications should be continued as prescribed.

Mechanism Of Action

Evkeeza contains evinacumab, a fully human monoclonal antibody that selectively targets and inhibits angiopoietin-like protein 3 (ANGPTL3). ANGPTL3 is a critical regulator of lipid metabolism expressed primarily in the liver, modulating plasma lipid levels by inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL), enzymes responsible for hydrolyzing triglycerides and phospholipids.

By binding to ANGPTL3 and neutralizing its activity, evinacumab diminishes ANGPTL3-mediated inhibition of lipolytic enzymes. This leads to enhanced clearance and breakdown of triglyceride-rich lipoproteins and low-density lipoprotein cholesterol (LDL-C). The result is a reduction in circulating levels of LDL cholesterol, very-low-density lipoprotein (VLDL), and other atherogenic lipoproteins.

In patients with homozygous familial hypercholesterolemia (HoFH), a genetic disorder characterized by defective or absent LDL receptors, traditional LDL-C lowering therapies have limited efficacy because they rely on LDL receptor-mediated clearance. Evkeeza acts through an LDL receptor-independent pathway to lower LDL-C by promoting catabolism of lipoproteins via increased lipase activity.

Clinical trials have demonstrated that evinacumab produces significant reductions in LDL-C levels when used as adjunct therapy in HoFH patients. This unique mechanism targeting ANGPTL3 provides an innovative therapeutic approach distinct from statins or PCSK9 inhibitors, representing a novel class of antihyperlipidemic agents. Research continues to explore broader applications of ANGPTL3 inhibition in lipid disorders and cardiovascular risk reduction.

Pharmacological Actions

Binds and inhibits angiopoietin-like protein 3 (ANGPTL3), a regulator of lipid metabolism.
Enhances lipoprotein lipase and endothelial lipase activity, facilitating lipid breakdown.
Reduces circulating low-density lipoprotein cholesterol (LDL-C) levels independently of LDL receptor function.
Lowers triglycerides and other atherogenic lipoproteins in addition to LDL-C.
Exhibits potent lipid-lowering effects in patients with homozygous familial hypercholesterolemia (HoFH).
Acts as a monoclonal antibody providing targeted, specific inhibition of a key metabolic protein.
Demonstrates once-monthly intravenous dosing suitability due to prolonged half-life.
Does not rely on hepatic cytochrome P450 metabolism, minimizing drug interaction risk.
Shows low immunogenicity as a fully human monoclonal antibody.
Provides an adjunctive treatment option for difficult-to-treat inherited hyperlipidemia.
Maintains long-term lipid-lowering efficacy with consistent monthly administration.
Modulates lipid metabolism through a novel biochemical pathway distinct from statins and PCSK9 inhibitors.
Improves lipid profiles contributing to potential reduction of cardiovascular risk in HoFH patients.
Demonstrates predictable pharmacokinetics and dynamics in adult and adolescent populations.
May be combined safely with other lipid-lowering agents to achieve target LDL-C reduction.

Therapeutic Or Clinical Uses

Treatment of homozygous familial hypercholesterolemia (HoFH) in adults and children aged 5 years and older.
Adjunct therapy to other lipid-lowering treatments for patients with inherited high LDL cholesterol.
Reduction of low-density lipoprotein cholesterol (LDL-C) in patients with deficient LDL receptor activity.
Management of refractory hypercholesterolemia unresponsive to conventional therapies.
Clinical use in patients with elevated risk for cardiovascular events due to severely elevated LDL-C.
Potential therapy for genetic lipid disorders involving disordered lipid metabolism pathways.
Treatment option for lowering triglycerides and other atherogenic lipoproteins in addition to LDL-C.
Indicated for use when diet and other medications are insufficient to control lipid levels in HoFH.
May reduce the risk of atherosclerotic cardiovascular disease in genetically predisposed individuals.
Utilized in specialized lipid clinics focusing on inherited dyslipidemias.
Supports personalized medicine approaches targeting specific molecular pathways of lipid regulation.
Provides a novel pharmacotherapeutic alternative to PCSK9 inhibitors in certain patients.
May be considered in combination regimens with statins, ezetimibe, or other lipid modifiers.
Therapeutic effects documented in controlled clinical trials with LDL-C as a primary endpoint.
Used in patients who cannot tolerate or have contraindications to other lipid-lowering therapies.

Side Or Adverse Effects

Infusion-related reactions including dizziness, nausea, headache, and flushing during administration.
Common cold or flu-like symptoms such as fever, chills, body aches, stuffy nose, sneezing, and sore throat.
Pain in extremities including arms or legs reported during or after infusion.
Fatigue or lack of energy that may persist transiently following treatment.
Hypersensitivity reactions including rash, itching, hives, and potential anaphylaxis.
Swelling of the face, lips, tongue, or throat indicating possible allergic reactions requiring emergency care.
Respiratory symptoms like wheezing, difficulty breathing, or chest tightness during infusion.
Potential for delay or discontinuation of treatment if severe adverse events occur.
Injection site erythema or irritation may occur but is less common with IV administration.
No significant hepatic or renal toxicity observed in clinical studies to date.
No reported effects on pregnancy except potential risk requiring use of effective contraception.
Transient hypotension or light-headedness during infusion requiring monitoring.
Gastrointestinal disturbances such as nausea or mild vomiting rarely reported.
No evidence of immunogenicity leading to neutralizing antibodies impacting therapy efficacy.
Adverse event profile consistent with monoclonal antibody therapies targeting circulating proteins.

Precautions

Prior to treatment, assess for hypersensitivity or allergy to evinacumab or excipients.
Women of childbearing potential should use effective contraception during treatment and for at least 5 months after the last dose.
Pregnancy testing is recommended before initiation as evinacumab may cause fetal harm.
Caution advised in patients with history of severe allergic reactions or asthma.
Monitor for infusion-related reactions during and after administration; be prepared to manage severe reactions.
Use cautiously in patients with active infections or immunocompromised status due to immunomodulatory effects.
Evaluate baseline liver and renal function, although no specific adjustments are recommended.
Concomitant use with other lipid-lowering agents should be supervised by healthcare provider.
Patients should be counseled on adherence due to monthly infusion schedule to maintain LDL-C control.
Educate patients on recognizing signs of allergic reactions or infusion side effects.
Avoid pregnancy during treatment owing to potential embryotoxicity observed in preclinical studies.
Breastfeeding safety is not established; weigh potential risks versus benefits.
Report any unexpected side effects promptly to healthcare providers.
Advise on lifestyle modifications including diet and exercise as complementary to pharmacotherapy.
Ensure appropriate storage and handling of the biological product to maintain efficacy.

Warnings

Use only as directed by a healthcare provider experienced in managing lipid disorders.
Evinacumab may cause serious allergic or hypersensitivity reactions including anaphylaxis.
Avoid use in patients with known hypersensitivity to evinacumab or any components of the formulation.
Pregnancy category: potential risk of fetal harm; effective contraception mandatory throughout treatment and 5 months post-treatment.
Monitor patients closely for infusion reactions; stop or slow infusion if symptoms occur.
Efficacy and safety in patients under 5 years of age have not been established; avoid use.
The impact on cardiovascular morbidity and mortality has not been determined.
Do not use Evkeeza to treat hypercholesterolemia unless caused by homozygous familial hypercholesterolemia.
Notify physician immediately if signs of allergic reaction develop during or after infusion.
Missed doses may result in loss of LDL-C control; timely rescheduling important.
Potential immunogenicity requiring monitoring for antibody development.
Not a substitute for dietary management; continue appropriate lifestyle measures.
Use with caution in patients with compromised immune function.
Advise patients not to self-administer; requires healthcare professional supervision.
Discard any unused product per proper protocols to maintain safety.

Contraindication

Known hypersensitivity to evinacumab or any component of Evkeeza injection.
Use in patients younger than 5 years of age due to lack of safety and efficacy data.
Patients with a history of severe allergic reactions or anaphylaxis to monoclonal antibodies.
Not indicated for treatment of hypercholesterolemia not caused by homozygous familial hypercholesterolemia (HoFH).
Pregnancy, unless potential benefits outweigh risks and with strict contraceptive measures.
Breastfeeding unless benefits outweigh potential risks, due to lack of human data.
Severe uncontrolled infections where immunomodulation may worsen condition.
Concurrent administration of other investigational monoclonal antibodies without adequate data.
Known hypersensitivity to any excipients such as polysorbate 80 or amino acid stabilizers.
History of hypersensitivity reactions during prior evinacumab infusions.
Administration outside a supervised healthcare setting due to risk of infusion reactions.
Patients unwilling or unable to comply with monthly IV infusion requirements.
Not intended for use as monotherapy where other lipid-lowering agents are clinically indicated.
Contraindicated in patients with hypersensitivity to humanized monoclonal antibodies in general only if related to evinacumab.
Avoid use if there is any unresolved acute hypersensitivity or allergy concerns.

Drug Interactions

No significant CYP450-mediated drug interactions expected due to monoclonal antibody metabolism.
Potential interaction with other lipid-lowering agents; monitor lipid levels to adjust therapy accordingly.
Concomitant use with statins, ezetimibe, or PCSK9 inhibitors generally safe and used adjunctively.
No known interactions with vitamins or herbal supplements but disclosure to clinician advised.
No specific interactions reported with anticoagulants or antiplatelet agents.
Limited data on interactions with immunosuppressants; caution advised when co-administered.
No effect on drugs metabolized by renal clearance or hepatic enzymes observed.
Avoid concurrent use with investigational drugs without safety data on combination.
No clinically relevant interaction with common over-the-counter medications.
Immunogenicity may be affected by concomitant immunomodulatory therapies.
No documented interaction with contraceptives; however, effectiveness of birth control should still be maintained.
Potential theoretical interaction with agents affecting vascular permeability or immune response.
Monitoring advised when combined with agents that influence lipid metabolism pathways.
No pharmacokinetic interaction reported with drugs affecting protein binding.
Drug interaction profiles not well studied in pediatric populations under 12 years.

Preparations Of The Drug

Evkeeza is supplied as a sterile, preservative-free intravenous infusion solution.
Available in single-dose vials containing either 1,200 mg per 8 mL or 345 mg per 2.3 mL at 150 mg/mL concentration.
Formulated with inactive ingredients including L-arginine hydrochloride, L-histidine, L-histidine monohydrochloride monohydrate, L-proline, polysorbate 80, and water for injection.
Stored refrigerated between 2°C and 8°C (36°F to 46°F); protect from light and freezing.
Before administration, vials should be inspected visually for particulate matter or discoloration and discarded if present.
Do not shake the vial vigorously; gentle inversion mixes the solution adequately.
Dilution is not required; drug is administered directly from vial via intravenous infusion over 60 minutes.
Single-use vials; discard any unused portion per hazardous waste guidelines.
Prepared aseptically to maintain sterility; use within recommended time after vial puncture.
Must be administered by healthcare professionals trained in IV infusion techniques.
Patient education materials provided outlining storage, handling, and potential adverse effects.
Comes with manufacturer’s prescribing information and patient medication guide.
No oral formulations available for evinacumab; only intravenous route approved.
No biosimilar products have yet been approved; Evkeeza is the reference product (Regeneron Pharmaceuticals).
Manufactured under strict quality control by Regeneron Pharmaceuticals, Inc.
Disposal of unused drug should follow institutional policies for biological agents.